The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma.
 
Jacqueline T. Brown
Consulting or Advisory Role - Exelixis; Xencor
Research Funding - Hookipa Pharma (Inst); Medicenna (Inst); Merck (Inst); Surface Oncology (Inst); Xencor (Inst)
 
Bassel Nazha
Honoraria - Intellisphere, LLC (Onclive)
Consulting or Advisory Role - Cardinal Health; Exelixis; IntrinsiQ
 
Yuan Liu
No Relationships to Disclose
 
Kelsea Lozada
No Relationships to Disclose
 
Jeremy D. Smith
No Relationships to Disclose
 
Caitlin Hartman
No Relationships to Disclose
 
Greta Russler McClintock
No Relationships to Disclose
 
Omer Kucuk
No Relationships to Disclose
 
Bradley Curtis Carthon
No Relationships to Disclose
 
R. Donald Harvey
Consulting or Advisory Role - EMD Serono; Janssen Oncology; Ribometrix
Research Funding - Janssen Research & Development (Inst); Meryx Pharmaceuticals (Inst); MorphoSys
 
Mehmet Asim Bilen
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; SeaGen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)